Evidence map›Paper›PMID 34998898›Full record

ReviewMolecular and cellular endocrinology2022

Ceramide signaling in the gut.

Ying Li, Rebekah J Nicholson, Scott A Summers

Open access · greenAbstract readReview
In one paragraph

Review in Molecular and cellular endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mating regulates growth, metabolism, and digestive efficiency in the femaleProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Microbiology spectrum · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Dietary and metabolic effects on intestinal stem cells in health and disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Lipidomics of Caco-2 Cells Under Simulated Microgravity Conditions.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ying LiDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, 15 North 2030 East, UT, 84112, Salt Lake City, USA. Electronic address: li.ying@utah.edu.
Rebekah J NicholsonDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, 15 North 2030 East, UT, 84112, Salt Lake City, USA.
Scott A SummersDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, 15 North 2030 East, UT, 84112, Salt Lake City, USA.
University of Utah · US

Funding

Interdisciplinary Training Program in MetabolismT32DK091317 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI SCOTT A SUMMERS · 2011 to 2026
$4.8M
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR44DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2018 to 2022
$4.7M
The Role of Ceramides in Skeletal MuscleR01DK115824 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2018 to 2021
$2.6M
The Role of Ceramides in the Intestinal Stem CellR01DK131609 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI EDGAR, BRUCE ALEXANDER, SUMMERS, SCOTT A · 2021 to 2025
$2.5M
The Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2M
Targeting a Ceramide Double Bond to Treat Cardiometabolic DisordersR01DK122001 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2019 to 2022
$1.9M
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR43DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2017 to 2017
$225k
NIDDK NIH HHS R01 DK115824NIDDK NIH HHS R01 DK122001NIDDK NIH HHS R01 DK130296NIDDK NIH HHS R01 DK131609NIDDK NIH HHS R43 DK116450NIDDK NIH HHS R44 DK116450NIDDK NIH HHS T32 DK091317
6 · The paper itself

Abstract

Sphingolipids are essential lipid components in the intestinal epithelial cells (IEC) along the intestinal tract. They play crucial roles in maintaining barrier integrity, regulating nutrient absorption, and acting as signaling molecules to regulate regeneration and differentiation of intestinal mucosa (Kurek et al., 2012). Ceramide is the central sphingolipid species and the precursor of all complex sphingolipids and other downstream simple intermediates like sphingosine (SPH), ceramide-1-phosphate (C-1-P), and sphingosine-1-phosphate (S-1-P). It is also a critical signaling molecule regulating numerous physiologic and pathologic processes. This review will summarize the metabolism of ceramides in the gut and their regulation in inflammatory bowel diseases and colorectal cancer.

Indexed as

Inflammatory Bowel DiseasesLysophospholipidsCeramidesHumansIntestinal MucosaSignal TransductionSphingolipidsSphingosineCeramidesLysophospholipidsSphingolipidsSphingosineCeramideColon cancerInflammatory bowel diseaseIntestineNAFLD

Identifiers

PMID34998898
PMCPMC8828712
OpenAlexW4205780979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.